Alkhars Naemah, Gaca Anthony, Zeng Yan, Al-Jallad Nisreen, Rustchenko Elena, Wu Tong Tong, Eliav Eli, Xiao Jin
Department of General Dental Practice, College of Dentistry, Health Science Center, Kuwait University, Safat 13110, Kuwait.
Translational Biomedical Science Program, Clinical and Translational Science Institute, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA.
J Fungi (Basel). 2023 May 17;9(5):580. doi: 10.3390/jof9050580.
The carriage of in children's oral cavities is associated with a higher risk for early childhood caries, so controlling this fungus in early life is essential for preventing caries. In a prospective cohort of 41 mothers and their children from 0 to 2 years of age, this study addressed four main objectives: (1) Evaluate in vitro the antifungal agent susceptibility of oral isolates from the mother-child cohort; (2) compare susceptibility between isolates from the mothers and children; (3) assess longitudinal changes in the susceptibility of the isolates collected between 0 and 2 years; and (4) detect mutations in antifungal resistance genes. Susceptibility to antifungal medications was tested by in vitro broth microdilution and expressed as the minimal inhibitory concentration (MIC). clinical isolates were sequenced by whole genome sequencing, and the genes related to antifungal resistance, , , , , , and , were assessed. Four spp. (n = 126) were isolated: , and . Caspofungin was the most active drug for oral , followed by fluconazole and nystatin. Two missense mutations in the gene were shared among isolates resistant to nystatin. Most of the children's isolates had MIC values similar to those from their mothers, and 70% remained stable on antifungal medications from 0 to 2 years. For caspofungin, 29% of the children's isolates showed an increase in MIC values from 0 to 2 years. Results of the longitudinal cohort indicated that clinically used oral nystatin was ineffective in reducing the carriage of in children; novel antifungal regimens in infants are needed for better oral yeast control.
儿童口腔中白色念珠菌的携带与幼儿龋齿风险较高相关,因此在生命早期控制这种真菌对于预防龋齿至关重要。在一项对41名母亲及其0至2岁儿童的前瞻性队列研究中,本研究有四个主要目标:(1)体外评估母婴队列中口腔白色念珠菌分离株对抗真菌药物的敏感性;(2)比较母亲和儿童分离株之间的白色念珠菌敏感性;(3)评估0至2岁期间收集的分离株敏感性的纵向变化;(4)检测白色念珠菌抗真菌耐药基因中的突变。通过体外肉汤微量稀释法测试对抗真菌药物的敏感性,并以最低抑菌浓度(MIC)表示。通过全基因组测序对临床分离株进行测序,并评估与抗真菌耐药性相关的基因,即ERG11、FKS1、FKS2、CDR1、CDR2、MDR1和TAC1。分离出四种白色念珠菌(n = 126):白色念珠菌、光滑念珠菌、近平滑念珠菌和热带念珠菌。卡泊芬净是对口腔白色念珠菌最有效的药物,其次是氟康唑和制霉菌素。在对制霉菌素耐药的白色念珠菌分离株中共有两个ERG11基因错义突变。大多数儿童的白色念珠菌分离株的MIC值与其母亲的相似,并且70%在0至2岁期间对抗真菌药物保持稳定。对于卡泊芬净,29%的儿童分离株在0至2岁期间MIC值有所增加。纵向队列研究结果表明,临床使用的口服制霉菌素在减少儿童白色念珠菌携带方面无效;需要新的婴儿抗真菌治疗方案以更好地控制口腔酵母菌。